TOTAL: $344.74M | ||||
Company (Symbol)# | Type Of Financing | Number Of Shares, Units Or Warrants (M) | Amount Raised (M) | Investors; Placement Agents; Details (Date)@ |
Advanced Biotherapy Inc. (OTC BB:ADVB) | Private placement of convertible subordinated debt | N/A | $1.5 | Cappello Capital Corp. was the placement agent for the transaction (12/20) |
AltaRex Corp. (Canada; TSE:AXO; ALRXF) | Private placement of common shares | 3.5S | C$7.75 (US$5.14) | AltaRex placed 3.5M shares with Dompe Farma- ceutici SpA at C$2.20 per share (12/22) |
Aradigm Corp. (ARDM) | Private placement of common shares | 0.115S | $2.2 | Aradigm sold 114,795 shares of its common stock to Acqua Wellington North American Equities Fund Ltd. for $2.2M (12/13) |
Aviron (AVIR) | Private placement of common stock | 0.142S | $8 | Aviron sold 142,205 shares to Acqua Wellington North American Equities Fund Ltd. for $8M, or $56.26 per share (12/28) |
Focal Inc. (FOCL) | Private placement of common shares | 2.4S | $5 | Focal agreed to sell 2.4M shares of its stock to Genzyme Surgical Products (GZSP) as part of a sales, marketing and financing agreement (12/11) |
Gilead Sciences Inc. (GILD) | Private placement of convertible subordinated notes | N/A | $250 | Gilead said it would sell $250M of convertible subordinated notes to institutional investors in a private placement, and will add $50M to the offering to cover overallotments, if any; the notes will have a seven-year term and will be redeemable after Dec. 20, 2003 (12/14) |
Hemosol Inc. (Canada; TSE:HML) | Subordinated credit financing | N/A | $12.5 | Hemosol entered a $12.5M subordinated credit financing with The Manufacturers Life Insurance Company (12/19) |
Interleukin Genetics Inc. (ILGN) | Private placement of common stock and warrants | 0.5S and 0.14W | $2 | Interleukin Genetics raised $2M in a private placement with a worldwide investor; the placement was managed entirely by the company and involved the issuance of 542,373 shares of common stock priced at $3.6875 and 135,593warrants priced at $4.83 each (12/19) |
NeoGene Technologies Inc. (unit of Neotherapeutics Inc.; NEOT) | Private placement of preferred stock | N/A | $2 | NeoGene raised $2M through the private placement of preferred stock with Societe Generale that is convertible into a 4% ownership interest (12/20) |
Novavax Inc. (AMEX:NOX) | Private placement of convertible debentures | N/A | $25 | King Pharmaceuticals Inc. (NYSE:KG) agreed to make a $25M convertible debenture investment; the note is convertible into Novavax stock; Novavax received $20M and will receive an additional $5M when it files an NDA for Estrasorb (12/20) |
Phage Therapeutics International Inc. (OTC BB:PTXX) | Private placement of units consisting of stock and warrants | 2.143U | $5 | Seven purchasers paid $1.5M for 2.143 units, consisting of one share and one warrant to purchase stock; they will pay another $1.5M for another 2.143M units soon; with the exercise of the warrants the company expects to receive an additional $1M after the first step is completed and another $1M a year after the second step is completed; total raised will be $5M (12/20) |
Protalex Inc. (OTC BB:PRTX) | Private placement of common stock | N/A | $0.5 | Protalex raised $500,000 in a private placement of its common stock (12/12) |
Ribozyme Pharmaceuticals Inc. (RZYM) | Equity financing facility | Ribozyme signed an agreement with Acqua Wellington North American Equities Fund Ltd. to set up an equity financing facility covering the sale of up to $60M in stock over the next 28 months; the financing is pursuant to a shelf registration for the sale of up to 3M shares (12/29) | ||
SciClone Pharmaceuticals Inc. (SCLN) | Private placement of a senior unsecured convertible note | 0.408 | $4.9 | SciClone said UBS AG purchased a $4M senior unsecured convertible note that is convertible into 407,610 shares at $9.81 per share; SciClone also received $900,000 for granting the investor the right to purchase an additional $5.9M of convertible notes (12/19) |
Unigene Laboratories Inc. (OTC BB:UGNE) | Private placement of common stock | N/A | $21 | Unigene entered into an agreement with Fusion Capital Fund II LLC, which will purchase up to $21M of Unigene's common stock over a 24-month period; Gruntal & Co. LLC acted as the financial adviser (12/19) |
Notes: | ||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange. | ||||
* Non-U.S. currencies converted at the exchange rate on the date of the announcement. | ||||
@ Dates refer to the date of the press release. | ||||
TSE = Toronto Stock Exchange | ||||
OTC BB = Over The Counter Bulletin Board | ||||
